Home >> Allergy/Immunology >> Allergy/Immunology >> Baby Food >> Technology & Media >>

Severe Psoriasis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 110 | Code: MRS - 18265

Severe Psoriasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Severe Psoriasis - Pipeline Review, H1 2015’, provides an overview of the Severe Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Severe Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Severe Psoriasis - Overview 9
Pipeline Products for Severe Psoriasis - Comparative Analysis 10
Severe Psoriasis - Therapeutics under Development by Companies 11
Severe Psoriasis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Severe Psoriasis - Products under Development by Companies 14
Severe Psoriasis - Companies Involved in Therapeutics Development 16
Almirall, S.A. 16
Amgen Inc. 17
ApoPharma Inc. 18
Boehringer Ingelheim GmbH 19
Covagen AG 20
Eli Lilly and Company 21
Idera Pharmaceuticals, Inc. 22
Johnson & Johnson 23
Merck KGaA 24
Pfizer Inc. 25
Sandoz International GmbH 26
Sun Pharmaceutical Industries Inc. 27
Syntrix Biosystems, Inc. 28
UCB S.A. 29
Valeant Pharmaceuticals International, Inc. 30
XenoPort, Inc. 31
Severe Psoriasis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
adalimumab biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
adalimumab biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
aminopterin sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
baricitinib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BI-655066 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brodalumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
certolizumab pegol - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
COVA-322 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dimethyl fumarate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
etanercept biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
guselkumab - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IDP-118 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IMO-8400 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ixekizumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MSB-0010841 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
orilotimod potassium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PF-04965842 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
tildrakizumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
toreforant - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ustekinumab - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
XP-23829 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Severe Psoriasis - Recent Pipeline Updates 77
Severe Psoriasis - Dormant Projects 105
Severe Psoriasis - Discontinued Products 106
Severe Psoriasis - Product Development Milestones 107
Featured News & Press Releases 107
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List of Tables
Number of Products under Development for Severe Psoriasis, H1 2015 9
Number of Products under Development for Severe Psoriasis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Development by Companies, H1 2015 (Contd..1) 15
Severe Psoriasis - Pipeline by Almirall, S.A., H1 2015 16
Severe Psoriasis - Pipeline by Amgen Inc., H1 2015 17
Severe Psoriasis - Pipeline by ApoPharma Inc., H1 2015 18
Severe Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 19
Severe Psoriasis - Pipeline by Covagen AG, H1 2015 20
Severe Psoriasis - Pipeline by Eli Lilly and Company, H1 2015 21
Severe Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 22
Severe Psoriasis - Pipeline by Johnson & Johnson, H1 2015 23
Severe Psoriasis - Pipeline by Merck KGaA, H1 2015 24
Severe Psoriasis - Pipeline by Pfizer Inc., H1 2015 25
Severe Psoriasis - Pipeline by Sandoz International GmbH, H1 2015 26
Severe Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 27
Severe Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2015 28
Severe Psoriasis - Pipeline by UCB S.A., H1 2015 29
Severe Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 30
Severe Psoriasis - Pipeline by XenoPort, Inc., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Severe Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 77
Severe Psoriasis - Dormant Projects, H1 2015 105
Severe Psoriasis - Discontinued Products, H1 2015 106

List of Figures
Number of Products under Development for Severe Psoriasis, H1 2015 9
Number of Products under Development for Severe Psoriasis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Top 10 Targets, H1 2015 33
Number of Products by Stage and Top 10 Targets, H1 2015 33
Number of Products by Top 10 Mechanism of Actions, H1 2015 35
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35
Number of Products by Top 10 Routes of Administration, H1 2015 37
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38
Number of Products by Top 10 Molecule Types, H1 2015 39
Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing